Specify a stock or a cryptocurrency in the search bar to get a summary
Mineralys Therapeutics, Inc. Common Stock
MLYSMineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. Address: 150 N. Radnor Chester Rd., Radnor, PA, United States, 19087
Analytics
WallStreet Target Price
32.5 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures MLYS
Dividend Analytics MLYS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History MLYS
Stock Valuation MLYS
Financials MLYS
Results | 2019 | Dynamics |